JamesN.D., SpearsM.R., ClarkeN.W.Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol.2015; 67(6): 1028–1038.
2.
GlassT.R., TangenC.M., CrawfordE.D., ThompsonI.Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol.2003; 169(1): 164–169.
3.
EisenbergerM.A., BlumensteinB.A., CrawfordE.D.Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med.1998; 339(15): 1036–1042.
4.
AkazaH., HinotsuS., UsamiM.; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer.2009; 115(15): 3437–3445.
5.
SciarraA., SalcicciaS.A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy?Eur Urol.2014; 65(5): 905–906.
6.
GravisG., FizaziK., JolyF.Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol.2013; 14(2): 149–158.
7.
ParmeleeP.A., ThurasP.D., KatzI.R., LawtonM.P.Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc.1995; 43(2): 130–137.
8.
Bill-AxelsonA., GarmoH., HolmbergL.Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian prostate cancer group-4 randomized clinical trial. Eur Urol.2013; 64(6): 920–928.
9.
NguyenP.L., JeY., SchutzF.A.Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA.2011; 306(21): 2359–2366.
10.
BoorjianS.A., KarnesR.J., CrispenP.L., RangelL.J., BergstralhE.J., BluteM.L.Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol.2009; 182(6): 2708–2714.
11.
ChoueiriT.K., XieW., D'AmicoA.V.Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer.2009; 115(5): 981–987.
12.
PistersL.L., LeiboviciD., BluteM.Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol.2009; 182(2): 517–525.
